Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

MGMT unmethylation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

MGMT unmethylation	Glioma	MGMT unmethylation	Glioma	temozolomide + interferon α-2b Sensitive: B - Late Trials JAMA Netw Open - 4 days (New B) temozolomide + interferon α-2b Sensitive : B JAMA Netw Open - 4d	temozolomide + interferon α-2b Sensitive: B - Late Trials JAMA Netw Open - 4 days temozolomide + interferon α-2b Sensitive : B JAMA Netw Open - 4 days - (New B)
MGMT unmethylation	Glioblastoma	MGMT unmethylation	Glioblastoma	temozolomide Sensitive: B - Late Trials temozolomide Sensitive : B	temozolomide Sensitive: B - Late Trials temozolomide Sensitive : B
MGMT unmethylation	Glioblastoma	MGMT unmethylation	Glioblastoma	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3
MGMT unmethylation	Glioblastoma	MGMT unmethylation	Glioblastoma	cemiplimab + INO-5401 + INO-9012 Sensitive: C3 – Early Trials cemiplimab + INO-5401 + INO-9012 Sensitive : C3	cemiplimab + INO-5401 + INO-9012 Sensitive: C3 – Early Trials cemiplimab + INO-5401 + INO-9012 Sensitive : C3
MGMT unmethylation	Glioblastoma	MGMT unmethylation	Glioblastoma	VAL-083 Sensitive: C3 – Early Trials VAL-083 Sensitive : C3	VAL-083 Sensitive: C3 – Early Trials VAL-083 Sensitive : C3
MGMT unmethylation	Glioblastoma	MGMT unmethylation	Glioblastoma	pembrolizumab Resistant: C3 – Early Trials pembrolizumab Resistant : C3	pembrolizumab Resistant: C3 – Early Trials pembrolizumab Resistant : C3
MGMT unmethylation	Glioblastoma	MGMT unmethylation	Glioblastoma	NOX-A12 Sensitive: C3 – Early Trials NOX-A12 Sensitive : C3	NOX-A12 Sensitive: C3 – Early Trials NOX-A12 Sensitive : C3
MGMT unmethylation	Glioblastoma	MGMT unmethylation	Glioblastoma	temozolomide + ABT-888 Sensitive: C3 – Early Trials temozolomide + ABT-888 Sensitive : C3	temozolomide + ABT-888 Sensitive: C3 – Early Trials temozolomide + ABT-888 Sensitive : C3
MGMT unmethylation	Glioblastoma	MGMT unmethylation	Glioblastoma	abemaciclib Sensitive: C3 – Early Trials abemaciclib Sensitive : C3	abemaciclib Sensitive: C3 – Early Trials abemaciclib Sensitive : C3
MGMT unmethylation	Glioma	MGMT unmethylation	Glioma	nivolumab + aglatimagene besadenovec Sensitive: C3 – Early Trials nivolumab + aglatimagene besadenovec Sensitive : C3	nivolumab + aglatimagene besadenovec Sensitive: C3 – Early Trials nivolumab + aglatimagene besadenovec Sensitive : C3